title: Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
abstract: The combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis/Haemophilus influenza vaccine (DTPa-HBV-IPV/Hib: Infanrix™ hexa, GlaxoSmithKline Vaccines) is used for primary vaccination of infants in a range of schedules world-wide. Antibody persistence after 4 DTPa-HBV-IPV/Hib doses in the first 2 y of life has been documented, but long-term persistence data following the 3, 5, 11-12 months (3-5-11) infant vaccination schedule, employed for example in Nordic countries, are limited. We assessed antibody persistence in 57 5-year-old children who had received either DTPa-HBV-IPV/Hib or DTPa-IPV/Hib (Infanrix™-IPV/Hib, GlaxoSmithKline Vaccines) in the 3-5-11 schedule. Among DTPa-HBV-IPV/Hib recipients, 7/12 retained seroprotective antibody concentrations for diphtheria, 10/12 for tetanus, 5/12 for hepatitis and 10/12 for Hib. Detectable antibodies were observed for 0/12 children for pertussis toxin (PT), 12/12 for filamentous haemagglutinin (FHA) and 8/12 for pertactin (PRN). Among DTPa-IPV/Hib recipients, 28/45 retained seroprotective anti-diphtheria concentrations, 34/44 for tetanus and 40/45 for Hib. Detectable antibodies were observed for 9/45 children for PT, 41/45 for FHA and 34/45 for PRN. Antibody persistence in DTPa-HBV-IPV/Hib and DTPa-IPV/Hib-vaccinees appeared similar in 5 y olds to that previously observed in children of a similar age who had received 4 prior doses of DTPa-HBV-IPV/Hib (or DTPa-IPV/Hib). As in subjects primed with 4 prior doses, we observed that antibodies markedly declined by 5 y of age, calling for the administration of a pre-school booster dose in order to ensure continued protection against pertussis.
authors.affiliation: a Department of Clinical Sciences; Pediatrics ; Umeå University ; Umeå , Sweden.
authors.forename: Sven A
authors.initials: SA
authors.lastname: Silfverdal
authors.forename: Deepak
authors.initials: D
authors.lastname: Assudani
authors.forename: Sherine
authors.initials: S
authors.lastname: Kuriyakose
authors.forename: Olivier
authors.initials: O
authors.lastname: Van Der Meeren
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology; D000917:Antibody Formation; D001886:Bordetella pertussis / Q000276:immunology; D002675:Child, Preschool; D003017:Clostridium tetani / Q000276:immunology; D003353:Corynebacterium diphtheriae / Q000276:immunology; D004165:Diphtheria / Q000276:immunology / Q000517:prevention & control; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology*; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000276:immunology; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology*; D013742:Tetanus / Q000276:immunology / Q000517:prevention & control; D014611:Vaccination; D017778:Vaccines, Combined / Q000276:immunology; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control
chemical_list: D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D011054:Poliovirus Vaccine, Inactivated; D017778:Vaccines, Combined; C541235:diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine
keywords: CI, confidence interval; DTPa-HBV-IPV/Hib, - diphtheria-tetanus-acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine; DTPa-IPV/Hib, diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b vaccine; FHA, filamentous haemagglutinin; GMC, geometric mean antibody concentration; HBs, anti-hepatitis B surface antigen; Hib, Haemophilus influenzae type b; NA, not applicable; PRN, pertactin; PRP, polyribosylribitol phosphate; PT, pertussis toxin; antibody persistence; booster; vaccination schedule; vaccine; μg/ml, micrograms per milliliter